Clinical Scorecard: Machine Learning Models Utilizing Clinical Parameters to Forecast Intraoperative Hemodynamic Instability in Patients with Hypertensive Pheochromocytomas and Paragangliomas
At a Glance
Category
Detail
Condition
Hypertensive pheochromocytomas and paragangliomas (PPGLs)
Key Mechanisms
Excessive catecholamine secretion causing systemic effects and intraoperative hemodynamic instability
Target Population
Patients with sustained hypertension and unilateral PPGLs undergoing laparoscopic or robotic surgery
Care Setting
Preoperative and intraoperative surgical care in tertiary hospital setting
Key Highlights
Sustained hypertensive PPGL patients have a threefold higher risk of intraoperative hypertensive emergencies and hypotensive episodes compared to normotensive PPGL patients.
Catecholamine secretion affects inflammatory responses, coagulation, and erythrocyte morphology, which may predict intraoperative hemodynamic instability.
Machine learning models can integrate clinical, laboratory, and tumor parameters to predict intraoperative hemodynamic instability risk in hypertensive PPGL patients.
Guideline-Based Recommendations
Diagnosis
Confirm PPGL diagnosis postoperatively via pathological examination.
Define sustained hypertension as office SBP ≥140 mmHg and/or DBP ≥90 mmHg on ≥2 visits or 24-h ambulatory SBP/DBP ≥130/80 mmHg.
Evaluate urinary catecholamines and blood catecholamine metabolites preoperatively using high-performance liquid chromatography methods.
Management
Preoperative adrenergic alpha-receptor blockade (phenoxybenzamine or terazosin) for at least two weeks before surgery.
Use laparoscopic or robotic surgical approaches for tumor excision.
Exclude patients with severe inflammation, infection, or hematologic disorders to reduce confounding risks.
Monitoring & Follow-up
Monitor intraoperative blood pressure closely to detect hemodynamic instability.
Kidney cancer is a growing global health problem, and both clinicians and policymakers need to prepare for a steep rise in the number of cases,” said Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, and senior author of a landmark international study published in European Urology, which demonstrates that if current trends continue, kidney cancer cases could double by 2050